AVBP — ArriVent BioPharma, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1868279 ·
Last close
$16.71
Market Cap
$823.93M
52W High
$35.83
52W Low
$11.36
ADV30
1,407,520
Next earnings
2026-11-16
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -52,691,000 | -49,893,000 | 394,718,000 | 154,682,000 | 27,877,000 |
| Mar 2026 | 0 | — | -46,111,000 | -43,320,000 | 349,295,000 | 62,103,000 | 25,315,000 |
| Dec 2025 | 0 | — | -38,823,000 | -35,544,000 | 333,169,000 | 45,540,000 | 25,945,000 |
| Sep 2025 | 0 | — | -38,316,000 | -34,978,000 | 326,555,000 | 112,672,000 | 21,558,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-134,472,000
Investing CF
$-104,467,000
Financing CF
$251,177,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.59
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-447,961,000
Inventory
—
Receivables
$60,000
ST Investments
$264,277,000
EBIT TTM
$-156,873,000
Pretax Income TTM
$-145,241,000
Interest Exp TTM
—
Analysts
10
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -177,534,000 | -166,308,000 | 333,169,000 | 25,945,000 | 307,224,000 | -160,588,000 |
| Dec 2024 | 0 | -94,308,000 | -80,488,000 | 274,942,000 | 17,288,000 | 257,654,000 | -70,212,000 |
| Dec 2023 | 0 | -74,590,000 | -69,333,000 | 163,098,000 | 316,291,000 | -153,193,000 | -55,842,000 |
| Dec 2022 | 0 | -36,906,000 | -36,906,000 | 182,833,000 | 267,942,000 | -85,109,000 | -43,631,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-145,241,000
OpCashFlow TTM
—
Assets (Latest)
$349,295,000
Forward EPS
$-3.81
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ABUS | Arbutus Biopharma Corp | $828.08M | $4.18 | — |
| ARDX | ARDELYX, INC. | $844.27M | $3.27 | — |
| CYRX | Cryoport, Inc. | $855.97M | $16.90 | — |
| CRVS | Corvus Pharmaceuticals, Inc. | $858.87M | $10.21 | — |
| PAHC | PHIBRO ANIMAL HEALTH CORP | $789.35M | $37.40 | — |
News headlines (Yahoo Finance, 1h cache)
Shanghai Allist shares slide after U.S. partner’s lung cancer drug trial fails
2026-10-08 05:38 · Yahoo
ArriVent’s stock plummets on Phase III NSCLC trial failure
2026-10-07 14:50 · Yahoo
AVBP Stock Crashes More Than 48% To All-Time Low After Lung Cancer Trial Setback – Retail Calls It ‘Way Undervalued’
2026-10-06 17:50 · Yahoo
ArriVent collapses on disappointing lung cancer data
2026-10-06 16:12 · Yahoo
Why This Biotech Stock Is Having Its Worst Day Ever
2026-10-06 15:53 · Yahoo
ArriVent Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion Mutant NSCLC
2026-10-06 12:00 · Yahoo
ArriVent BioPharma Reports Second Quarter 2026 Financial Results
2026-08-12 20:01 · Yahoo
ArriVent BioPharma Reports First Quarter 2026 Financial Results
2026-05-11 20:01 · Yahoo
A Look At ArriVent BioPharma (AVBP) Valuation After FDA Clears ARR-002 Oncology Candidate
2026-05-10 06:08 · Yahoo
ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers
2026-05-07 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.